Pds Biotechnology Corporation Stock Price, News & Analysis

PDS Biotechnology Corporation (PDSB) announced promising preclinical results of its investigational platform, Infectimune™, which demonstrated robust immune responses to SARS-CoV-2 and influenza viruses. Published in the journal Viruses, the study showed that Infectimune™ induced strong T cell and neutralizing antibody responses, offering complete protection in animal models against lethal viral challenges.

The research indicates potential for developing next-generation universal vaccines, facilitating significant dose sparing of viral proteins. PDS Biotech is advancing its Infectimune™ programs, highlighting long-lasting immune memory and efficacy against infectious diseases.

PDS Biotechnology Corporation (PDSB) announced that an abstract, titled “HPV16-specific CD4 and CD8 T cell activation and functionality in patients receiving combination PDS0101 immunotherapy,” has been accepted for presentation at the ESMO Targeted Anticancer Therapies Congress 2023 in Paris, taking place from March 6-8, 2023. The study investigates PDS0101, an HPV-targeted immunotherapy used in combination with KEYTRUDA (pembrolizumab), focusing on its effects on T cell activation in patients with advanced recurrent or metastatic HPV16-positive head and neck cancer. The findings aim to enhance understanding of drug-induced immune responses and their relationship with clinical outcomes.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company, announced its participation in the Channelchek Takeaway Series during the J.P. Morgan Healthcare Conference on January 26, 2023, at 10:00 a.m. EST. CEO Frank K. Bedu-Addo will discuss the company's business and clinical development strategy in a session followed by Q&A with Noble Capital Markets' Senior Analyst Robert LeBoyer. The Channelchek Takeaway Series aims to connect healthcare executives with investors, offering insights into PDS Biotech's product candidates, including PDS0101, which has shown promising results in HPV16-associated cancers.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy firm, announced participation in the B. Riley Securities 3rd Annual Oncology Conference, set for January 18-19, 2023. A fireside chat with management will occur on January 19, 2023, at 1:00 PM EST, accessible via livestream. PDS Biotech focuses on developing targeted immunotherapies for cancer and infectious diseases using its proprietary Versamune^® and Infectimune™ platforms, showing promise in clinical trials for HPV-expressing cancers.

PDS Biotech has announced an exclusive global license agreement with Merck KGaA for the IL-12 fusion protein M9241, now referred to as PDS0301. The agreement includes a $5 million upfront payment and potential milestone payments totaling up to $116 million, along with a 10% royalty on future sales. M9241 is designed to enhance T cell effectiveness in tumor environments.

Clinical data shows promising results in treating advanced HPV-positive cancers, with significant improvements in survival rates and tumor response compared to standard therapies. A meeting with the FDA is scheduled to discuss a registrational trial.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced promising interim results from its Phase 2 trial of PDS0101, a triple therapy for HPV16-positive cancers. The data revealed a median overall survival (OS) of 21 months in 29 checkpoint inhibitor (CPI) refractory patients, compared to a historical median of 3-4 months. Among CPI-naive patients, 75% remained alive at a median follow-up of 27 months. The objective response rate was 63% in CPI refractory and 88% in CPI naive patients. The trial demonstrates the therapy's durability and tolerability, with 48% reporting Grade 3 adverse events.

PDS Biotechnology Corporation announced the completion of enrollment in the first stage of its VERSATILE-002 Phase 2 study, investigating PDS0101 in combination with Merck’s KEYTRUDA for recurrent and/or metastatic HPV16-positive head and neck cancer. Positive preliminary data from 17 patients showed a 41% objective response rate and 87% overall survival at nine months. The study targets both checkpoint inhibitor refractory and naïve patients, with potential advancements based on initial efficacy results. This highlights a critical milestone in the company's pursuit to improve treatment options for advanced head and neck cancers.

PDS Biotechnology Corporation (PDSB) announced preliminary results from its PDS0101 Phase 2 clinical studies at SITC 2022, highlighting 100% clinical response in locally advanced cervical cancer patients. The company reported a successful end-of-Phase 2 meeting with the FDA for VERSATILE-002, advancing to a registrational trial. Financially, PDSB experienced a net loss of $7.4 million for Q3 2022, slightly up from $7.0 million in Q3 2021, driven by increased R&D costs. The cash balance as of September 30, 2022, stood at $71.6 million, supporting ongoing clinical programs.

PDS Biotechnology Corporation (PDSB) recently presented updated data from its ongoing IMMUNOCERV Phase 2 clinical trial at the Society for Immunotherapy of Cancer (SITC 2022). The study, which explores PDS0101 combined with standard chemoradiotherapy (CRT) for advanced cervical cancer, reported that 100% of patients exhibited tumor shrinkage of over 60% at midpoint evaluations. Additionally, 89% showed no evidence of disease by day 170. The data indicates that PDS0101 effectively activates HPV16-specific T cells, suggesting a promising new treatment approach for cervical cancer.